Looking at some of the latest news from Biomira.Apparently there is not much interest on BIOM around here, as there are no postings since early June.<g>
EDMONTON, Nov. 9 /PRNewswire-FirstCall/ -- Biomira Inc. (NASDAQ:BIOM) (TSX:BRA) of Edmonton, Alberta, Canada, announced today that data from a Phase Ib clinical research trial to test the safety and immunogenicity of its autologous vaccine for the treatment of B-cell lymphoma will form the basis of an oral presentation at the 2004 Annual Meeting of the American Society of Hematology (ASH) in San Diego.
Sattva S. Neelapu, M.D., of the MD Anderson Cancer Center in Houston, TX, is to present the data. The trial was carried out under a Collaborative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI) in 2001.
The oral presentation is scheduled for 9:30 a.m., Tuesday, December 7th, 2004. The meeting is to be held from December 4th to 7th, 2004.
prnewswire.com
The stock had been acting well lately after the recent news on L-BLP25 which seems to have a better potential than Theratope.Earlier reports of the results of L-BLP25 on mice were impressive and the latest reports, especially on patients on an early stage seem promising.
The PII on Ovarian Cancer to be carried out by Prima-BioMed using dendritic cells sensitized ex-vivo may have possible good results, but those are somewhat far away and BIOM's potential benefit from that is through its 10% ownership of Prima-BMD subsidiary CancerVac.
BIOM's spurt in revenues in the 2ndQ was due to the $5.9M recognition into income from Merk KGa in connection with Theratope. At that time cash reserves were around $30.7M (down about $10.M from previous year.)On October 30th that amount was down to $26.8M or almost 4M for the Q.
The stock has closed its Jul.29 up-gap and may now test support at the 1.24 level. The nearest resistance is at 1.56 and there is a more important one at 1.75
bigcharts.marketwatch.com.
Bernard |
